Horizon scanning: FDA accepts New Drug Application for AnoroT (umeclidinium bromide and vilanterol) for COPD

Source: BioSpace Area: News GlaxoSmithKline plc has announced that the New Drug Application for AnoroT, a combination of two investigational bronchodilator molecules: umeclidinium bromide, and vilanterol, for the treatment of chronic obstructive pulmonary disease (COPD), has been accepted by the US Food and Drug Administration (FDA). The once-daily combination medicine is administered using the ElliptaT inhaler.
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news